Sherene Loi1, Urania Dafni2, Dimitris Karlis3, Varvara Polydoropoulou4, Brandon M Young5, Scooter Willis5, Bradley Long6, Evandro de Azambuja7, Christos Sotiriou8, Giuseppe Viale9, Josef Rüschoff10, Martine J Piccart11, Mitch Dowsett12, Stefan Michiels13, Brian Leyland-Jones5. 1. Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. 2. Frontier Science Foundation- Hellas, Athens, Greece3University of Athens, Athens, Greece. 3. Frontier Science Foundation- Hellas, Athens, Greece4Athens University of Economics and Business, Athens, Greece. 4. Frontier Science Foundation- Hellas, Athens, Greece. 5. Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota. 6. Department of Pathology, University of Chicago, Chicago, Illinois. 7. BREAST Datacentre, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium. 8. Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium. 9. University of Milan, European Institute of Oncology, Milan, Italy. 10. Targos Molecular Pathology GmbH, Kassel, Germany. 11. Department of Medicine, Institute Jules Bordet, Universite Libre de Bruxelles and Breast International Group (BIG), Brussels, Belgium12Breast International Group (BIG), Brussels, Belgium. 12. Royal Marsden Hospital, London, England. 13. INSERM U1018 CESP, Service de Biostatistique et d'Epidémiologie, Villejuif, France.
Abstract
IMPORTANCE: A number of studies suggest that response to antihuman epidermal growth factor receptor-2 (currently known as ERBB2, butreferred to asHER2 in this study) agents differs by estrogen receptor (ER) level status. The clinical relevance of this is unknown. OBJECTIVE: To determine the magnitude of trastuzumab benefit according to quantitative levels of ER and HER2 in the HERceptin Adjuvant (HERA) trial. DESIGN, SETTING, AND PARTICIPANTS: The HERA trial was an international, multicenter, randomized trial that included 5099 patients with early-stage HER2-positive breast cancer, randomized between 2001 and 2005 to receive eitherno trastuzumab or trastuzumab, after adjuvant chemotherapy. This is a secondary analysis of the HERA study. Local ER immunohistochemical (IHC) analyses, HER2 fluorescence in situ hybridization (FISH) ratio, and copy number results were available for 3037 patients (59.6%) randomized to observation and trastuzumab (1 or 2 years) (cohort 1). Transcript levels of ESR1 and HER2 genes were available for 615 patients (12.1%) (cohort 2). INTERVENTIONS: Patients were randomized to receive either no trastuzumab or 1 year vs 2 years of trastuzumab. Endocrine therapy was given to patients with hormone receptor-positive disease as per local guidelines. MAIN OUTCOMES AND MEASURES: Disease-free survival (DFS) and overall survival (OS) were the primary and secondary end points in the intent-to-treat population (ITT). Analyses adjusting for crossover (censored and inverse probability weighted [IPW]) were also performed. Interactions among treatment, ER status, and HER2 amplification using predefined cutoffs were assessed in Cox proportional hazards regression models. RESULTS: Median follow-up time was 8 years. Levels of FISH and HER2 copy numbers were significantly higher in ER-negative patients (P < .001). In cohort 1, for DFS and OS, a significant treatment effect was found for all ER, IHC, and FISH levels, except for the ER-positive/HER2 low FISH ratio (≥2 to <5) group (DFS: 3-way ITT Pvalue for interaction = .07; censored = .02; IPW = .03; OS ITT Pvalue for interaction = .007; censored = .04; IPW = .03). In cohort 2, consistent with cohort 1, a significant predictive effect of the ESR1 gene for both end points was also observed (DFS Pvalue for interaction = .06; OS = .02), indicating that breast cancers with higher ESR1 levels also derive less benefit from trastuzumab. CONCLUSIONS AND RELEVANCE: Patients with HER2-positive breast cancers that are ER-positive by IHC analyses with low FISH ratio (≥2 to <5), or with higher ESR1 levels derive significantly less benefit from adjuvant trastuzumab after chemotherapy. These data may explain heterogeneity in response to anti-HER2 agents in HER2-positive, ER-positive breast cancers as some may be more luminal-like than HER2 driven. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00045032.
RCT Entities:
IMPORTANCE: A number of studies suggest that response to antihuman epidermal growth factor receptor-2 (currently known as ERBB2, butreferred to asHER2 in this study) agents differs by estrogen receptor (ER) level status. The clinical relevance of this is unknown. OBJECTIVE: To determine the magnitude of trastuzumab benefit according to quantitative levels of ER and HER2 in the HERceptin Adjuvant (HERA) trial. DESIGN, SETTING, AND PARTICIPANTS: The HERA trial was an international, multicenter, randomized trial that included 5099 patients with early-stage HER2-positive breast cancer, randomized between 2001 and 2005 to receive either no trastuzumab or trastuzumab, after adjuvant chemotherapy. This is a secondary analysis of the HERA study. Local ER immunohistochemical (IHC) analyses, HER2 fluorescence in situ hybridization (FISH) ratio, and copy number results were available for 3037 patients (59.6%) randomized to observation and trastuzumab (1 or 2 years) (cohort 1). Transcript levels of ESR1 and HER2 genes were available for 615 patients (12.1%) (cohort 2). INTERVENTIONS:Patients were randomized to receive either no trastuzumab or 1 year vs 2 years of trastuzumab. Endocrine therapy was given to patients with hormone receptor-positive disease as per local guidelines. MAIN OUTCOMES AND MEASURES: Disease-free survival (DFS) and overall survival (OS) were the primary and secondary end points in the intent-to-treat population (ITT). Analyses adjusting for crossover (censored and inverse probability weighted [IPW]) were also performed. Interactions among treatment, ER status, and HER2 amplification using predefined cutoffs were assessed in Cox proportional hazards regression models. RESULTS: Median follow-up time was 8 years. Levels of FISH and HER2 copy numbers were significantly higher in ER-negative patients (P < .001). In cohort 1, for DFS and OS, a significant treatment effect was found for all ER, IHC, and FISH levels, except for the ER-positive/HER2 low FISH ratio (≥2 to <5) group (DFS: 3-way ITT Pvalue for interaction = .07; censored = .02; IPW = .03; OS ITT Pvalue for interaction = .007; censored = .04; IPW = .03). In cohort 2, consistent with cohort 1, a significant predictive effect of the ESR1 gene for both end points was also observed (DFS Pvalue for interaction = .06; OS = .02), indicating that breast cancers with higher ESR1 levels also derive less benefit from trastuzumab. CONCLUSIONS AND RELEVANCE: Patients with HER2-positive breast cancers that are ER-positive by IHC analyses with low FISH ratio (≥2 to <5), or with higher ESR1 levels derive significantly less benefit from adjuvant trastuzumab after chemotherapy. These data may explain heterogeneity in response to anti-HER2 agents in HER2-positive, ER-positive breast cancers as some may be more luminal-like than HER2 driven. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00045032.
Authors: Berit M Pfitzner; Bianca Lederer; Judith Lindner; Christine Solbach; Knut Engels; Mahdi Rezai; Karel Dohnal; Hans Tesch; Martin L Hansmann; Christoph Salat; Michaela Beer; Andreas Schneeweiss; Peter Sinn; Agnes Bankfalvi; Silvia Darb-Esfahani; Gunter von Minckwitz; Bruno V Sinn; Ralf Kronenwett; Karsten Weber; Carsten Denkert; Sibylle Loibl Journal: Mod Pathol Date: 2017-12-22 Impact factor: 7.842
Authors: Emad A Rakha; Islam M Miligy; Cecily M Quinn; Elena Provenzano; Abeer M Shaaban; Caterina Marchiò; Michael S Toss; Grace Gallagy; Ciara Murray; Janice Walshe; Ayaka Katayama; Karim Eldib; Nahla Badr; Bruce Tanchel; Rebecca Millican-Slater; Colin Purdie; Dave Purnell; Sarah E Pinder; Ian O Ellis; Andrew H S Lee Journal: Br J Cancer Date: 2021-03-24 Impact factor: 7.640
Authors: Valeriy Domenyuk; Zoran Gatalica; Radhika Santhanam; Xixi Wei; Adam Stark; Patrick Kennedy; Brandon Toussaint; Symon Levenberg; Jie Wang; Nianqing Xiao; Richard Greil; Gabriel Rinnerthaler; Simon P Gampenrieder; Amy B Heimberger; Donald A Berry; Anna Barker; John Quackenbush; John L Marshall; George Poste; Jeffrey L Vacirca; Gregory A Vidal; Lee S Schwartzberg; David D Halbert; Andreas Voss; Daniel Magee; Mark R Miglarese; Michael Famulok; Günter Mayer; David Spetzler Journal: Nat Commun Date: 2018-03-23 Impact factor: 14.919
Authors: Tamera J Lillemoe; Mara Rendi; Michaela L Tsai; Monica Knaack; Rina Yarosh; Erin Grimm; Barbara Susnik; Janet Krueger; Susan Olet; Karen K Swenson Journal: Int J Breast Cancer Date: 2021-05-24